Huntington’s Disease – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of HD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of HD for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and the other countries covered in this report. In addition to forecasting the incident patient population, we estimate the number of drug-treatment opportunities in the mature markets.
Clarivate Epidemiology’s HD forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with HD per year?
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with HD per year?
- How will improvements in survival change the number of people living with a diagnosis of HD?
- How will the declining risk of recurrence change the number of people diagnosed with HD per year?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following HD patient populations:
- Diagnosed manifest prevalent cases.
- Diagnosed manifest incident cases.
- Diagnosed manifest prevalent cases by drug treatment scheme.
- Diagnosed manifest prevalent cases by stage of disease.
- Diagnosed prevalent cases.
- Diagnosed premanifest prevalent cases.
- Diagnosed prevalent cases at risk.
- Diagnosed prevalent cases by risk category.
Note: Coverage may vary by country and region.
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.